Ameay Naravane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ameay Naravane has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Rocio Montezuma
Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, USA
3 shared publications - Aaron Nagiel
Vision Center - Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA; Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
1 shared publication Adam C. Janot
1 shared publicationAdam Hanif
1 shared publicationAudina Berrocal
1 shared publicationCharles Li
American Academy of Ophthalmology, San Francisco, California
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in Ophthalmology Retina
Clinical Features, Retinal Detachment Rates, and Retinal Detachment Prophylaxis in Patients with Genetically Confirmed Knobloch Syndrome
- 8 September 2026
- Published by Elsevier in Ophthalmology Retina
Open AccessClinical Features, Retinal Detachment Rates, and Retinal Detachment Prophylaxis in Patients with Genetically Confirmed Knobloch Syndrome
- 17 June 2023
- Published by Springer Nature
- p. 385-398
Incontinentia Pigmenti
- Open Access
- 20 January 2023
- Published by Elsevier in Ophthalmology Science
- Vol. 3 (3) , 100273
Vitreoretinopathy-Associated Pediatric Retinal Detachment Treatment Outcomes
- 20 January 2023
- Published by Elsevier in Ophthalmology Science
- Vol. 3 (3) , 100273
Open AccessVitreoretinopathy-Associated Pediatric Retinal Detachment Treatment Outcomes
- Open Access
- 17 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0247161
Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study
Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (RVO). This study aims to assess the effect of unintended delays in anti-VEGF treatment during the first wave of the COVID-19 pandemic. This retrospective case series identified patients receiving regularly scheduled anti-VEGF intravitreal injections based on current procedural terminology (CPT) code at two practices in Minnesota. Diagnoses were limited to nAMD, diabetic macular edema (DME), proliferative diabetic retinopathy, and RVO. Patients were divided into two groups based on whether they maintained or delayed their follow-up visit by more than two weeks beyond the recommended treatment interval during the COVID-19 lockdown. The ‘COVID-19 lockdown’ was defined as the period after March, 28th, 2020, when a lockdown was declared in Minnesota. We then compared the visual acuity and structural changes to the retina using ocular coherence tomography (OCT) to assess whether delayed treatment resulted in worse visual outcomes. A total of 167 eyes from 117 patients met criteria for inclusion in this study. In the delayed group, the average BCVA at the pre- and post-lockdown visits were 0.614 and 0.715 (logMAR) respectively (p = 0.007). Central subfield thickness (CST) increased from 341 to 447 in the DME delayed group (p = 0.03) while the CST increased from 301 to 314 (p = 0.4) in the nAMD delayed group. The results of this pilot study suggests that treatment delays may have a negative impact on the visual and anatomic outcomes of patients with nAMD and DME. Future studies with larger sample sizes are required for further investigation.
- 17 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0247161
Open AccessShort term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study
Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (RVO). This study aims to assess the effect of unintended delays in anti-VEGF treatment during the first wave of the COVID-19 pandemic. This retrospective case series identified patients receiving regularly scheduled anti-VEGF intravitreal injections based on current procedural terminology (CPT) code at two practices in Minnesota. Diagnoses were limited to nAMD, diabetic macular edema (DME), proliferative diabetic retinopathy, and RVO. Patients were divided into two groups based on whether they maintained or delayed their follow-up visit by more than two weeks beyond the recommended treatment interval during the COVID-19 lockdown. The ‘COVID-19 lockdown’ was defined as the period after March, 28th, 2020, when a lockdown was declared in Minnesota. We then compared the visual acuity and structural changes to the retina using ocular coherence tomography (OCT) to assess whether delayed treatment resulted in worse visual outcomes. A total of 167 eyes from 117 patients met criteria for inclusion in this study. In the delayed group, the average BCVA at the pre- and post-lockdown visits were 0.614 and 0.715 (logMAR) respectively (p = 0.007). Central subfield thickness (CST) increased from 341 to 447 in the DME delayed group (p = 0.03) while the CST increased from 301 to 314 (p = 0.4) in the nAMD delayed group. The results of this pilot study suggests that treatment delays may have a negative impact on the visual and anatomic outcomes of patients with nAMD and DME. Future studies with larger sample sizes are required for further investigation.
- 1 September 2020
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 3 (5) , 339-342
Inpatient Adherence to Topical Glaucoma Medications before and after an Educational Intervention
- 1 September 2020
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 3 (5) , 339-342
Inpatient Adherence to Topical Glaucoma Medications before and after an Educational Intervention